SITE008-0199

SITE008 (KOR) › SITE008-0199

SITE008-0199

A Phase III, Randomized, Double-Blind Study of Torivumab Plus Chemotherapy Versus Placebo Plus Chemotherapy in Previously Untreated Advanced Non-Small Cell Lung Cancer · Phase III
SITE008 (KOR) · Dr. Kim
consented 2026-04-26

enrolled

AEs

2

Serious

1

Dropout signal

–

Adverse events

2

Grade 1 Fatigue — outcome: RECOVERED/RESOLVED; onset 2023-02-16 (study day 104); relationship: not assessed

mild assessed

Grade 4 Alopecia — outcome: RECOVERED/RESOLVED; onset 2022-12-21 (study day 47); relationship: not assessed; serious criteria: life-threatening

severe serious assessed

Data queries

0

No data queries. Open queries would appear here for this patient.